UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________________________ Delaware 88-0488 ...

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non- GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non- GAAP Diluted EPS of $0.82 1 SAN DIEGO, February 20, 2024 -- Halozyme Therapeutics, ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Michael DiFiore - Evercore ISI Corinne Jenkins - Goldman Sachs Jason Butler - JMP Securities Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C Wainwright Oper ...

Dollar amounts, as presented, are rounded. Consequently, totals may not add up. (1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the Antares acquisition. (2) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition. (3) Amounts relate to fair value gain on contingent liability, inventory write-off and impairment of TLANDO® product rights intangible assets due to the termination of the T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. 12390 El Camino Real 92130 San Diego (Zip Code) California (Ad ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 AM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference Call Participants Mohit Bansal - Wells Fargo Michael DiFiore - Evercore ISI David Risinger - Leerink Partners Jason Butler - JMP Securities Mitchell Kapoor - H.C. Wainwright Mack Chandler - Jefferies Caroline Palomeque - Berenberg Capital Markets Operator Good afternoon, my n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ____________ ...

NASDAQ: HALO May 2023 Forward Looking Statements Non-GAAP Financial Measures: Note: This presentation contains product names, trademarks and registered trademarks that are property of their respective owners. | --- | --- | --- | |-------------------------------------------------------------------------|--------------------------------------------------------|-------------------------------------------| | ENHANZE ® | Drug Delivery Platform Technologies \nAuto-Injectors | Commercial Portfolio \nSpecialty Prod ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Na Sun - JPMorgan Corinne Jenkins - Goldman Sachs Mohit Bansal - Wells Fargo Michael DiFiore - Evercore ISI Roy Buchanan - JMP Securities David Risinger - SVB Securities Caroline Palomeque - Ber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________ ...